2. Needle Free Injection INJEX Technology and Products

Transcription

1

2 Disclaimer This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "indents", "plans", "believes", "seeks", "estimates", "will", "may" or words of similar meaning. Such statements are based on our current expectations and assumptions, and therefore are subject to various risks and uncertainties that could cause the actual results, performance or achievements to differ materially from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. The company does not assume any obligations to update or revise any of these forward-looking statements, even if new information becomes available in the future. 2

3 INJEX Pharma Group 1. INJEX Pharma: The Company 2. INJEX Pharma: Technology and Products 3. INJEX Pharma: The Story so far 4. INJEX Pharma Group: Deploy for the Future 5. Business Development: Partner with Pharma 6. Our Vision for the Future 7. Contact Information 3

4

5 2. Needle Free Injection INJEX Technology and Products Needle Syringe Needle-Free Injection Pool of Medication left by needle Needle free psychological effect Only little risk for injuries; eliminates cross contamination Almost painless injection 5 Medication is dispensed uniformly in spray like pattern

6 2. Needle Free Injection INJEX Technology and Products Poring: Injex SiliTop Adapter (Poring-Tip) enables intradermal injections In the standard case, the drug is dispersed in the subcutaneous tissue. In conjunction with the SiliTop and a modified spring force, the drug is distributed in the upper skin compartments (Dermis; intradermal injections). 6

7 2. Needle Free Injection INJEX Technology and Products The Injex30 System provides important advantages to patients: virtually painless and needle-free skin/tissue preserving convenient for delivering variable doses flexible use of insulin / mixing possible = just one injection easy and safe in use and effect no risk of needle-stick injuries / infections no risk of infection because of no frequent needle usage eliminates cross-contamination can be disposed in domestic waste / reduces disposal costs user friendly, compact and can be used everywhere easy to operate and long-lasting eliminates psychological oppositions and fears: needle-phobia reliable, subcutaneous injection extensive avoidance of dermis trauma 7

8 3. INJEX Pharma Group: The Story so far Status Quo Manufacturer of needle-free medical devices to be used for Heparin, Vaccination, Antiallergics, Fertility treatments, Interferon and other intradermal and subcutaneous* treatments Next Steps Cooperations with pharma will develop additional applications and therapeutic solutions for INJEX30 Our Goal Become the pharma partner for device and delivery solutions Current Business Model: keep Technology Central develop applications and Sales Regional * tissues under the skin 8

9 3. INJEX Pharma Group: The Story so far Dual Business Strategy: The Unique Approach of INJEX Pharma Medical Technology Market Basis for high volume business; markets highly regulated and different in most countries; different regional marketing approaches required Beauty Treatment Market Basis for Life Style business, ww similar Rules of the Game allow global marketing approach 9

10 3. INJEX Pharma Group: The Story so far Needle free is a fast growing market INJEX30 INJEX Beauty Line New Design of Boxes to be introduced shortly Medical Markets Cosmetic Markets Dental Botox Injections Local Anesthetics Hyaluronic Injections Diabetes The global market for needle free injection devices will be at 4,5 billion $ in 2022 (Vision Gain Research) 10

11 3. INJEX Pharma Group: The Story so far Medical Market INJEX- vs. Pen Injection 6 : Transdermal Application improves Pharmacokinetics Insulin kinetics and pharmacology genotropien Mean dose GH Needle Injex Time from dose in hrs 11 6) Schatz,H., Pfohl,M. et al., Ruhr-Univ. Bochum, 36 th Annual Conference of the German Diabetes Society (DDG)

12 3. INJEX Pharma Group: The Story so far Beauty Market Number of annual cosmetic procedures: fast growing high margin market Injectables: Botulinum Toxin Type A (Botox, Dysport) 3,766,148 3,257,913 Calcium hydroxyapatite (Radiance) 160, ,674 Hyaluronic Acid (including Juvederum, Perlane / Restylane, Belotero, Pevelle, Elevess) 1,872,172 1,423,705 Poly-L-Lactic Acid (Sculptra) 87,946 69,965 Total Injectables 5,887,192 4,881,258 Injectables overall (including Botox, Xeomin, Dysport, Radiesse, Juvederm Ultra, Ultra Plus, Voluma, Perlane, Restylane, Belotero, Poly-L-Lactic acid, etc.) saw a 21% increase in 2013, with 5,887,192 procedures performed Source: American Society for Aesthetic Plastic Surgery, Statistics 2013, published March 15,

13 4. INJEX Pharma Group: Deploy for the Future Continuously improved Products and Services to our Customers Medical Markets INJEX30 New ERP-System allows tracking of each product and confirms origination New Web-based services provided Develop new autoclavable version for dentists Injex Academy established for training b e c o 13 INJEX Beauty Line Cosmetic Markets Cooperate with a firstclass provider for (crosslinked) Hyaluronic Injections New ERP-System New Web-based Services provided Injex Academy established for training These Improvements may be quickly completed and they do not need new registrations and/or approvals

14 4. INJEX Pharma Group: Deploy for the Future Develop Injex Next Generation Products Injector Develop the new Type of Injector 2.0 independent from the Reset Box (to be launched in late 2017) Study feasibility to develop a derivative 0,5 ml Injector Ampoules b e c o Get access to the 0,3 ml Pre-filled Ampoule Technology based on Polycarbonat and develop it to marketability (Technology Agreement with japanese R&D Group; to be launched in late 2017) If feasibility for 0,5 ml is confirmed, get access to the 0,5 ml Technology Services & Clinical Development Continiously improve Web-based Support Perform a Clinical Study to prove enhanced Pharmacokinetics 14

15 5. Business Development: Partner with Pharma New Developments in the Industry will further fuel INJEXs Growth Potential New markets for the INJEX30-System for intradermal use R&D divisions of pharmaceutical and biotech companies have developed new drugs for dermal and intradermal applications Target was to reduce the amount of injected volume for the intradermal injection for short term efficacy Vaccines, which were injected intramuscularly with 1 ml 10 years ago, are injected with 0.1 ml intradermal today So the trend is our friend 15

16 5. Business Development: Partner with Pharma R&D Strategy: Examples for potential Applications of existing Injectables Source: 10k, Antares 16

17 6. Our Vision for the Future upgrade from a Device Manufacturer to a Pharma Partner as Solutions Provider for Transdermal Therapies and Applications Clinical Studies showed bioequivalence in Molecular Integrity and Efficacy Pharmacokinetics and -dynamics Experiences from Specialists show therapeutic advantages to be statistically proven by clinical studies Clinical Observatory Trial est. to start in Q4/ 2016 Become the Drug Delivery Company 17

18 7. Contact Information INJEX Pharma Group Headquarter: Suzhou/China R&D, Manufacturing, Regulatory: Berlin/Germany Business Development, Sales&Marketing: New York/USA t. b. est. Dr. Thomas Klaue, CEO Tel.: +49 (0) Web.: (under construction)